ILC Therapeutics Announces Successful Completion of £3.5m Funding Round
ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.
- ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a ground-breaking new class of interferon drugs, announces the successful completion of a 3.5m pre- IPO funding round.
- Chairman Peter Bains said: We are very pleased to complete this important funding round and to strengthen the Board with the appointment of Robert Kopple, Professor David Harrison and Chris Brinsmead.
- ILC Therapeutics Ltd is an emerging biotechnology company focused on modulating the innate immune system through the design and development of novel hybrid interferon drug candidates.
- For more information on ILC Therapeutics, please visit: www.ilctherapeutics.com
Follow ILC Therapeutics on LinkedIn: www.linkedin.com/company/ilctherapeutics/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210906005255/en/